Last reviewed · How we verify
NCT03577808
Organoids in Predicting Chemoradiation Sensitivity on Rectal Cancer
trial testing Biopsy in Organoids in 80 participants. Status unknown.
1 August 2020
Quick facts
| Lead sponsor | Zhen Zhang |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 17 August 2018 |
| Primary completion | 1 August 2020 |
| Estimated completion | 1 November 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Biopsy — full drug profile →
Conditions studied
- Organoids — all drugs for Organoids →
- Rectal Cancer — all drugs for Rectal Cancer →
- Chemoradiation — all drugs for Chemoradiation →
Sponsor
Zhen Zhang
Who can join
Adults 18 to 75, any sex, with Organoids or Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with locally advanced rectal cancer will receive biopsy before the standard treatment of neoadjuvant chemoradiation. The investigators are going to establish organoids model from the pre-treatment biopsies and expose organoids to irradiation and the same chemotherapy drugs. The sensitivity of irradiation and chemotherapy drugs will be tested in the organoids model. Here, the investigators will launch the observational clinical trial to validate whether the organoids could predict the clinical outcome in locally advanced rectal cancer patients underwent neoadjuvant chemoradiation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03577808
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biopsy
Trials testing the same drug.
- NCT06675123 — Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lym · Phase 1 · recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT06860815 — Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Br · Phase 2 · recruiting
- NCT05741164 — Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory · Phase 2 · not yet recruiting
Other recruiting trials for Organoids
Currently open trials in the same condition.
- NCT06658080 — Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer · recruiting
- NCT06929845 — Organoid Models of Hepatocellular Carcinoma · NA · recruiting
- NCT06155305 — Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer · recruiting
- NCT06315868 — Breast Cancer Subtype Characterization Through Patient's Derived Organoids. · recruiting
- NCT05323357 — Bern Human Organoid-Study to Study Host-microbe Interaction · recruiting
Other Zhen Zhang trials
Trials by the same sponsor.
- NCT07383857 — PULSAR Radiotherapy Plus Anti-PD-1 Therapy in Metastatic Abdominopelvic Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03577808 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhen Zhang
- Last refreshed: 20 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03577808.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing